Date and Time | Title | |
---|---|---|
Jan 28, 2022 (Eastern) 3:00pm - 3:40pm | ICLUSIG®(ponatinib): Taking Action At The Critical Moment Sponsored by Takeda Oncology | |
Jan 29, 2022 (Eastern) 8:00am - 8:40am | Use of a Targeted Agent For Previously Untreated or R/R CLL This program presents clinical efficacy and safety data supporting the use of a selective Bruton tyrosine kinase inhibitor for the treatment of previously untreated and R/R CLL. Sponsored by AstraZeneca | |
Jan 29, 2022 (Eastern) 9:00am - 10:42am | Session I 9:00 am ET | Welcome and Introduction 9:05 am ET | Acute Myeloid Leukemia 9:28 am ET | Live Q&A 9:36 am ET | Myelodysplastic Syndromes 10:02 am ET | Live Q&A 10:11 am ET | Chronic Myeloid Leukemia 10:32 am ET | Live Q&A 10:41 am ET | Summary | |
Jan 29, 2022 (Eastern) 10:43am - 11:05am | Break JOIN US IN THE EXHIBIT HALL! | |
Jan 29, 2022 (Eastern) 11:05am - 12:40pm | Session I, Continued 11:05 AM ET | Welcome Back 11:10 AM ET | Acute Lymphocytic Leukemia 11:33 AM ET | Live Q&A 11:42 AM ET | Chronic Lymphocytic Leukemia 12:02 PM ET | Live Q&A 12:11 PM ET | Myeloproliferative Neoplasms 12:32 PM ET | Live Q&A 12:41 PM ET | Summary | |
Jan 29, 2022 (Eastern) 1:00pm - 1:40pm | Redefining Frontline Therapy In Patients With Multiple Myeloma* This presentation will discuss redefining frontline therapy in patients with multiple myeloma (MM) using DARZALEX® and DARZALEX FASPRO® *This presentation will be available on demand from February 1-April 1, 2022 Sponsored by Janssen | ![]() |
Feb 4, 2022 (Eastern) 12:00pm - 12:35pm | Brukinsa for the treatment of adult patients with Waldenström’s macroglobulinemia (WM) Sponsored by BeiGene | |
Feb 4, 2022 (Eastern) 3:00pm - 3:20pm | Continuous Proteasome Inhibition with NINLARO® (ixazomib) Offers Durable Efficacy and Manageable Tolerability for the Types of Patients You See Every Day Sponsored by Takeda Oncology | |
Feb 5, 2022 (Eastern) 9:00am - 10:35am | Session II 9:00 am ET | Welcome and Introduction 9:06 am ET | Newly Diagnosed Multiple Myeloma 9:26 am ET | Live Q&A 9:37 am ET | Relapsed/Refractory Myeloma 9:52 am ET | Live Q&A 10:03 am ET | Hodgkin and Indolent Non-Hodgkin Lymphoma 10:24 am ET | Live Q&A | |
Feb 5, 2022 (Eastern) 10:35am - 10:55am | Break | |
Feb 5, 2022 (Eastern) 10:55am - 12:00pm | Session II, Continued 10:55 am ET I Welcome Back 11:00 am ET | Aggressive Non-Hodgkin Lymphoma 11:21 am ET | Live Q&A 11:30 am ET | Benign Hematology 11:53 am ET | Live Q&A 12:01 pm ET | Summary | |
Feb. 22, 2022 - 3:30 pm to May. 23, 2022 - 3:30 pm (Eastern) | Hematologic Malignancies Demystified - Jan 29 & Feb 5th |